Project/Area Number |
25670224
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Virology
|
Research Institution | Tokyo Metropolitan Institute of Medical Science |
Principal Investigator |
KOHARA Michinori 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 特任研究員 (10250218)
|
Co-Investigator(Renkei-kenkyūsha) |
YASUI Fumihiko 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 主席研究員 (40399473)
MUNAKATA Tubasa 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 主席研究員 (50420237)
SAITO Makoto 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 研究員 (20433021)
MUNEKATA Keisuke 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 研究員 (30569140)
SUGA Hiroaki 東京大学, 大学院理学系研究科, 教授 (00361668)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | インフルエンザ / 特殊環状ペプチド / 感染阻害 / インフルエンザウイルス / HA蛋白質 / 抗ウイルス剤 / パントロピック / 増殖阻害 |
Outline of Final Research Achievements |
To devise smaller molecules capable of binding to the influenza viral HA and have the potential as an antiviral agent, we used an emerging technology, RaPID (Random non-standard Peptide Integrated Discovery) system. After five rounds selection of H5N1 HA-binding peptides, we found a total of 24 candidates for inhibitor HA (iHA). iHA inhibited plaque formation against different clade H5N1 viruses, A/whooper swan/Mongolia/3/05 (H5N1/Mongolia; clade 2.2) and A/whooper swan/Hokkaido/1/08 (H5N1/Hokkaido; clade 2.3). Intriguingly, iHA was effective against pandemic (H1N1) 2009 viruses more than zanamivir. These results suggest that iHA is able to inhibit replication of a wide range of H1 and H5 influenza viruses via a mechanism of its interaction with HA. Polykaryon formation mediated by various clade H5 HAs were also inhibited by iHA in a dose-dependent manner.
|